The miR-625-3p/AXL axis induces non-T790M acquired resistance to EGFR-TKI via activation of the TGF-β/Smad pathway and EMT in EGFR-mutant non-small cell lung cancer

Gefitinib is currently the preferred treatment for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-activating mutation. However, some patients gradually develop acquired resistance after receiving treatment. In addition to secondary T790M mutation, the remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Wenwen, Sun, Lin, Liu, Ting, Zhu, Jianjie, Zeng, Yuanyuan, Zhang, Yang, Wang, Xueting, Liu, Zeyi, Huang, Jian-An
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251657/
https://www.ncbi.nlm.nih.gov/pubmed/32319651
http://dx.doi.org/10.3892/or.2020.7579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251657/
https://www.ncbi.nlm.nih.gov/pubmed/32319651
http://dx.doi.org/10.3892/or.2020.7579

Ejemplares similares